Two smaller phase II studies have demonstrated efficacy of single-agent crenolanib in R/R FLT3-mutated AML, with a CR rate of 23−39% in patients naïve to FLT3 inhibitors, and 5% patients with prior FLT3 exposure (29, 30). The gene discussed is FLT3; the disease is acute myeloid leukemia.